Woden ACT, Australia
March 18, 2005
COMING
SOON
Your chance to comment on
the Risk Assessment and Risk Management Plan for proposed
dealings involving intentional release of genetically modified
cotton: DIR 058/2005
Applications
The Office of the Gene Technology
Regulator (OGTR) has
received an application under section 40 of the Gene
Technology Act 2000 (the Act)
from Deltapine Australia Pty
Ltd which, if approved, would involve a limited and
controlled release of genetically modified organisms (GMOs) into
the Australian environment.
Details of DIR 058/2005
are as follows:
The licence application proposes to conduct a field trial
of three genetically
modified insecticidal
cotton (Gossypium hirsutum) lines that have previously
been assessed and approved for limited and controlled release
under DIR licences issued to other applicants. The proposed
release would take place at two sites on a total of one hectare
over the 2005/06 summer season, in New South Wales and
Queensland. The GM
cotton lines contain an insect resistance gene derived from a
common soil bacterium. This gene produces a protein, known as
Vegetative Insecticidal Protein, that is toxic to certain
insects, including the major caterpillar pests of cotton. One
of the lines also contains a selectable marker gene that confers
resistance to the antibiotic hygromycin.
Purpose of this
notification
As the Gene Technology
Regulator, I would like to advise people who have previously
expressed interest in knowing about work with GMOs in Australia
that they now have the opportunity to access information about
this application, including the application itself.
You can obtain a copy of
the application from my Office (see contact details below).
When contacting the office, please quote the reference number of
the application you are interested in. As the application is
quite lengthy, you may prefer to view a summary of the
application, which is posted on our website with this document
(under “What’s New”). If you would like to receive a hard copy
of the summary, please contact us and we will post it to you.
A comprehensive ‘Risk
Assessment and Risk Management Plan’ (RARMP) for this
application is now being prepared with input from a broad range
of expert groups and stakeholders, including State and Territory
Governments, relevant local councils, key Australian Government
agencies, the Minister for the Environment and Heritage and the
Gene Technology Technical Advisory Committee. The RARMP is
expected to be released for public comment in mid June 2005.
If you have questions
about the application, or how you can provide comment, please
contact us at:
The Office of the Gene
Technology Regulator
PO Box 100
Woden, ACT, 2606
Website: www.ogtr.gov.au
E-mail: ogtr@health.gov.au
Phone: 1800 181 030
Fax: (02) 6271 4202
This document
in PDF format:
http://www.ogtr.gov.au/pdf/ir/dir058ebnotification.pdf
DIR 058/2005 -
cotton licence application summary
APPLICATION FOR LICENCE
FOR INTENTIONAL RELEASE OF GMOs INTO THE ENVIRONMENT:
Application No. DIR 058/2005
SUMMARY INFORMATION
Project Title: |
Small Scale Field
Trial of GM Insect Resistant (VIP) Cotton |
Applicant: |
Deltapine Australia Pty Ltd |
Common name of
the parent organism:
Scientific name
of the parent organism:
Modified
trait(s):
Identity of the gene(s) responsible for the modified trait(s):
|
Cotton
Gossypium hirsutum
Insect
resistance, antibiotic resistance
·
vip3A
gene from the bacterium Bacillus thuringiensis
(insect resistance)
·
aph4
gene from
Escherichia coli (antibiotic resistance)
|
Proposed
Location(s) |
Local Government
Area of Narrabri, New South Wales (NSW) and Local
Government Area of Emerald, Queensland (Qld) |
Proposed Release
Size: |
1 hectare |
Proposed Time of
Release |
September/October
2005 – July 2006 |
Introduction
The Gene Technology
Act 2000 (the Act) took effect on 21 June 2001. The Act,
supported by the Gene Technology Regulations 2001, an
inter-governmental agreement and corresponding legislation that
is being enacted in each State and Territory, underpins
Australia’s nationally consistent regulatory system for gene
technology. Its objective is to protect the health and safety of
people, and the environment, by identifying risks posed by or as
a result of gene technology, and managing those risks by
regulating certain dealings with genetically modified organisms
(GMOs).
The
Act establishes a statutory officer, the Gene Technology
Regulator (the Regulator), to administer the legislation and
make decisions under the legislation.
The Regulator is supported by the Office of the Gene Technology
Regulator (OGTR), an Australian Government regulatory agency
located within the Health and Ageing portfolio.
The legislation sets out
the requirements for considering applications for licences for
dealings with GMOs, which includes the preparation of a risk
assessment and risk management plan (RARMP) for each proposed
intentional release of a GMO into the environment, and the
matters that the Regulator must take into account before
deciding whether, or not, to issue a licence.
The application and the proposed dealings
The OGTR has received an
application from Deltapine Australia Pty Ltd (Deltapine) for a
licence for the intentional release of three genetically
modified (GM) cotton (Gossypium hirsutum) lines
into the environment, on a limited scale and under controlled
conditions.
Deltapine proposes to
carry out a field trial on two sites covering a total area of up
to one hectare (maximum of 0.5 hectare per trial site) over a
single summer season, 2005/2006. The trial would be conducted in
the Local Government Areas of Narrabri Shire, NSW and Emerald
Shire, Qld.
The GM cotton lines
proposed for release were originally imported from the United
States by CSIRO under AQIS import permits. They each contain
one of three different transformation events in the American
cultivar Coker 312 (this cultivar is often used as a starting
point of research as it is easily transformed in the
laboratory). The COT102 GM cotton line (COT102 line) contains
insect resistance (vip3A) and antibiotic resistance (aph4)
genes. The COT202 and COT203 lines contain only the insect
resistance gene, vip3A. The GM cotton lines produce
vegetative insecticidal protein (VIP) that is toxic to
lepidopteran caterpillar pests of cotton.
The aim of
the proposed release is to produce seed from the GM cotton
lines. The applicant anticipates using the seed in future
larger scale trials to transfer the insect resistance trait to
elite Australian cotton cultivars, evaluate the effectiveness of
protection and undertake target and non-target ecological
assessments. These trials would be the subject of future
applications and require separate assessments and approval
processes.
None of the cotton
plants from the release, or their by-products, would be used for
animal and human food. An approval from Food Standards
Australia New Zealand (FSANZ) would be required before oil from
cotton containing the vip3A gene could be used for human
consumption. However, the applicant proposes to sell lint from
the release for use as fibre in the textile industry. Lint does
not contain genetic material or protein.
Transport and storage of
the GM material would be conducted in accordance with the
guidelines issued by the Regulator. Following harvest, plant
material remaining at the site would be removed and/or
destroyed. Any cottonseed not required for research purposes or
possible future releases would also be destroyed.
Details of the gene
construct, including the plasmid map and regulatory sequences
for the COT102, COT202 and COT 203 cotton lines, have previously
been declared as Confidential Commercial Information (CCI) under
section 185 of the Act in connection with previous applications
(DIRs 017/2002 and 036/2003). However, the CCI will be made
available to the prescribed expert groups and agencies that will
be consulted on the preparation of the risk assessment and risk
management plan for this application.
Previous releases of the GMO
Under the former
voluntary system overseen by the Genetic Manipulation Advisory
Committee (GMAC), CSIRO conducted one similar limited and
controlled release of the COT102 line (PR-151). The release was
less than 0.05 hectare, and was carried out in NSW. In
addition, the Regulator previously issued licences approving the
limited and controlled release of:
Ø the
GM cotton line COT102 to CSIRO under DIR 017/2002 in NSW and
under DIR 025/2002 in north western Western Australia (WA);
Ø the
GM cotton line COT102 to Syngenta under DIR 034/2003 (however no
plantings occurred) in NSW and Qld; and
Ø the
GM cotton lines COT102, COT202 and COT203 to CSIRO under DIR
36/2003 (however no plantings occurred) in NSW and Qld.
There have been no
reports of adverse effects on human health or the environment
resulting from any of the releases that occurred.
Parent organism
The parent organism is
cultivated cotton (Gossypium hirsutum L.), which is
exotic to Australia and is grown as an agricultural crop in NSW
and southern Qld and on a trial basis in northern Qld, north
western WA and the NT.
Genetic modification and its effect
The COT102 GM cotton
line contains an insecticidal gene, vip3A, derived from a
common soil bacterium Bacillus thuringiensis (Bt). The
vip3A gene encodes a protein (VIP) that is toxic to the
major lepidopteran caterpillar pests of cotton (Helicoverpa
amigera and H. punctigera).
In addition to the
vip3A gene, the COT102 line contains a commonly used
selectable marker gene, aph4, from the bacterium
Escherichia coli that confers resistance to the antibiotic
hygromycin B. The marker gene enables identification of plant
tissues in which the insecticidal gene is being expressed during
the initial laboratory stage of development of the GMOs.
The COT202 and COT203
lines proposed for release have had the selectable marker gene,
aph4, removed through segregation in subsequent breeding
experiments and will therefore contain only the insect resistant
gene vip3A.
Short regulatory
sequences that control expression of the genes are also present
in all the GM cotton lines. Some of these are derived from a
plant and a common bacterium, Agrobacterium
tumefaciens. Although A. tumefaciens is a plant
pathogen, the regulatory sequences comprise only a small part of
its total genome, and are not in themselves capable of causing
disease.
Method of genetic modification
The GM cotton lines were
produced by introducing the vip3A and aph4 genes
into the Coker 312 cotton variety on a plasmid vector carried by
Agrobacterium tumefaciens. The vector is
‘disarmed’ since it lacks the genes that encode the
tumour-inducing functions of A. tumefaciens.
Consultation on preparation of the Risk Assessment and Risk
Management Plan
The Regulator has made
an initial assessment as to whether the proposed release may
pose significant risks to human health and safety or the
environment, in accordance with section 49 of the Act. Due to
the low risk potential of the GMOs, the control measures that
will be imposed, and the limited scale and scope of the
dealings, the Regulator has decided that the proposed release
does not pose a significant risk to human health and safety or
the environment.
This means that the
Regulator is not required to seek public comment on the
assessment of this proposal until after a risk assessment and
risk management plan (RARMP) has been prepared. In the interim,
copies of the application are available on request from the
OGTR. Please quote application number DIR 058/2005.
In preparing the RARMP,
the Regulator will seek input from a wide range of key
stakeholders and expert groups comprising State and Territory
Governments, relevant Australian Government agencies, the
Minister for the Environment and Heritage, the Gene Technology
Technical Advisory Committee and appropriate local councils, as
required by section 50 of the Act. In accordance with section
52 of the Act, the Regulator will again consult with these
prescribed agencies and authorities as well as the public in
finalising the RARMP.
At this
stage, the
consultation version of the
RARMP is
expected to be issued for consultation in mid June 2005.
The public will be invited to provide submissions on the RARMP
via advertisements in the media and direct mail to anyone
registered on the OGTR mailing list. Summaries and copies of
the RARMP will be available from the OGTR, or on the OGTR
website.
If you have any
questions abut the application or the assessment process, please
contact the OGTR at:
The Office of the
Gene Technology Regulator
PO Box 100
Woden, ACT, 2606
Website: www.ogtr.gov.au
E-mail: ogtr@health.gov.au
Phone: 1800 181 030
Fax: (02) 6271 4202
|